Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ADC Therapeutics Ltd (ADCT)
NYSE:ADCT
ADC Therapeutics (ADCT) Stock Price & Analysis
282 Followers
ADCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.36 - $6.04
Previous Close$3.44
Volume290.35K
Average Volume (3M)809.86K
Market Cap
$331.02M
Enterprise Value$176.76M
Total Cash (Recent Filing)$278.60M
Total Debt (Recent Filing)$124.35M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Aug 06, 2024EPS Estimate
-$0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.76
Shares Outstanding82,814,000
10 Day Avg. Volume733,037
30 Day Avg. Volume809,855
Standard Deviation0.29
R-Squared0.08
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-2.49
Price to Sales (P/S)3.15
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.26
Enterprise Value/Gross Profit2.66
Enterprise Value/Ebitda-1.71
Forecast
1Y Price Target
$8.67Price Target Upside152.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
ADC Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DataZynlonta achieved an overall response rate of 93.3% in the study, significantly higher than typical complete response rates in the second-line setting for MZL.
Financial PositionThe company's financial position is strengthened by an underwritten offering expected to raise substantial funds, providing a runway into the near future.
Market ExpansionADCT's management expects sales growth from expansion in both academic and community settings.
Bears Say
Clinical StudyStock was down ~15% owing to announcement of slightly higher censoring in the LOTIS-5 study.
Sales PerformanceADCT's sales of Zynlonta are slightly below consensus expectations for 1Q24.
Stock Price TargetAnalyst has slightly lowered the 12-month price target for the stock.
---
Ownership Overview
32.30% Insiders
9.13% Mutual Funds
3.35% Other Institutional Investors
55.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADCT FAQ
What was ADC Therapeutics Ltd’s price range in the past 12 months?
ADC Therapeutics Ltd lowest stock price was $0.36 and its highest was $6.04 in the past 12 months.
What is ADC Therapeutics Ltd’s market cap?
Currently, no data Available
When is ADC Therapeutics Ltd’s upcoming earnings report date?
ADC Therapeutics Ltd’s upcoming earnings report date is Aug 06, 2024 which is in 15 days.
How were ADC Therapeutics Ltd’s earnings last quarter?
ADC Therapeutics Ltd released its earnings results on May 06, 2024. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of -$0.556 by -$0.004.
Is ADC Therapeutics Ltd overvalued?
According to Wall Street analysts ADC Therapeutics Ltd’s price is currently Undervalued.
Does ADC Therapeutics Ltd pay dividends?
ADC Therapeutics Ltd does not currently pay dividends.
What is ADC Therapeutics Ltd’s EPS estimate?
ADC Therapeutics Ltd’s EPS estimate is -$0.45.
How many shares outstanding does ADC Therapeutics Ltd have?
ADC Therapeutics Ltd has 96,225,914 shares outstanding.
What happened to ADC Therapeutics Ltd’s price movement after its last earnings report?
ADC Therapeutics Ltd reported an EPS of -$0.56 in its last earnings report, missing expectations of -$0.556. Following the earnings report the stock price went down -9.184%.
Which hedge fund is a major shareholder of ADC Therapeutics Ltd?
Among the largest hedge funds holding ADC Therapeutics Ltd’s share is Grosvenor Holdings, L.L.C.. It holds ADC Therapeutics Ltd’s shares valued at 7M.
---
ADC Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.67 (152.03% Upside)
$8.67 (152.03% Upside)
Blogger Sentiment
Bullish
ADCT Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
129.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-34.15%
Trailing 12-Months
Company Description
ADC Therapeutics Ltd
ADC Therapeutics SA is a United States-based clinical-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ADCT-402, ADCT-301, ADCT-602, and ADCT-601.
---
ADCT Company Deck
---
ADCT Earnings Call
Q1 2024
0:00 / 0:00
---
ADCT Stock 12 Month Forecast
Average Price Target
$8.67
▲(152.03% Upside)
Technical Analysis
Best Analysts Covering ADCT
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
+38.99%
reiterated a buy rating 3 months ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +38.99% per trade.
---